Evidence & concentration worksheet · Hormonal & Sexual Health
PT-141 10 mg
Evidence supports named, regulated products and indications. A research powder or different vial strength does not inherit the approved product's formulation, reconstitution, storage, or dosing instructions.
Evidence review
Approved dosing is product-specific
Evidence supports named, regulated products and indications. A research powder or different vial strength does not inherit the approved product's formulation, reconstitution, storage, or dosing instructions.
How it works
PT-141 is a development name commonly used for bremelanotide. FDA approval belongs to the finished prescription product Vyleesi: a defined bremelanotide formulation and autoinjector, not to every vial sold online under the PT-141 name.[1]
The approved indication is acquired, generalized hypoactive sexual desire disorder that causes marked distress or interpersonal difficulty in premenopausal women and is not due to another medical or psychiatric condition, relationship problems, or a medication or drug substance. It is not indicated for men, postmenopausal women, or enhancement of sexual performance.[1]
Benefits & side effects
Two phase 3 randomized, double-blind, placebo-controlled trials in the labeled population supported statistically significant changes in prespecified sexual-desire and distress measures.[2] The label also states that there was no significant between-group difference in the change in satisfying sexual events, a secondary endpoint.[1]
The evidence supports the narrow approved population and product. It does not establish efficacy for erectile dysfunction, men, postmenopausal women, generalized libido enhancement, or an unverified compounded product.
Calculator
Concentration and measurement calculator
Use this only to check arithmetic from an authoritative product label, registered study protocol, or qualified clinician.
Arithmetic only — not a dose recommendation
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Source concentration
Source-supplied target
References
References
- DailyMed — Current Vyleesi (bremelanotide) labeling (2025)
- Obstetrics & Gynecology — Bremelanotide for HSDD: two randomized phase 3 trials (2019)
- U.S. FDA — Compounding and FDA: questions and answers (2026)